An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts.

@article{Khan2015AnIP,
  title={An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts.},
  author={Naeem Khan and Sylvie D. Freeman and Paul F Virgo and Steve Couzens and Peter L Richardson and Ian F Thomas and Angela Grech and Paresh Vyas and David J Grimwade and Nigel H. Russell and Alan K. Burnett and Robert K. Hills},
  journal={British journal of haematology},
  year={2015},
  volume={170 1},
  pages={80-4}
}
Many older patients with acute myeloid leukaemia (AML) that receive standard intensive chemotherapy fail to achieve complete remission (CR). Upfront identification of patients unlikely to benefit from standard induction chemotherapy would be important for exploration of novel therapies. This study evaluated if a flow cytometric assay measuring pre-treatment CD34(+) CD38(low) blast frequency could predict therapeutic-resistance in 736 AML patients entered into the UK National Cancer Research… CONTINUE READING

From This Paper

Topics from this paper.
2 Citations
0 References
Similar Papers

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…